Nitrous oxide is used for anesthetic procedures and widely used for analgesia, especially for children. It is often considered safe but some toxicities are described: hematologic and neurological. Inhibition of vitamin B12 function by NO is a well-described but rare adverse effect of prolonged or repeated exposure. Banks et al. 1 first described the effects of NO on hematologic precursors. NO leads to an irreversible inactivation of vitamin B12/cobalamine by oxidation of its cobalt core. Cobalamine is used as a co-enzyme of methionine synthetase (MS). MS transforms 5-methyltetrahydrofolate (THF) into THF. THF is then used for the synthesis of purine and pyrimidine nitrogenous bases of DNA ( Figure 1 ). The NO-related blockade has an effect on haematopoiesis similar to that observed in the case of vitamin B12 deficiency, leading to DNA synthesis impairment. Studying bone marrow cells from patients exposed to NO anesthesia, Kano et al. 2 reported a reduced 5-methyl-THF homocysteine methyltransferase activity after 4 h of NO exposure. The deoxyuridine suppression test, performed to quantify the conversion of deoxyuridine into deoxythymidine on bone marrow cells, is abnormal after NO exposition. 3 An increase of plasma homocystein concentration can be measured in blood samples and is directly correlated with the duration of NO exposure. 4 Badner et al. 5 reported another toxic effect of NO: the increased homocystein plasma level after NO exposure may expose patients to a higher risk of postoperative myocardial ischemia.
Here, we describe the case of a 16 year-old girl who presented with secondary bone marrow failure following allogeneic haploidentical stem cell transplant (SCT). The patient, an 11-year old girl was treated for AML with normal karyotype, and underwent a first SCT from her brother, after obtaining a first CR. Two years later, as the disease relapsed, the patient received a salvage regimen (gemtuzumab, Ara-C and fludarabine), leading to a second CR. Two years later, at the age of 16, a second relapse occurred and, after salvage chemotherapy, she underwent a second SCT from a haplo-identical donor. Pretransplant bone marrow analysis showed CR. The conditioning regimen was based on thiotepa, IV busulfan and fludarabine. Graft versus host-disease prophylaxis consisted of cyclosporine, mycophenolate mofetil and posttransplant cyclophosphamide. A total of 7.54 × 10 6 CD34+ cells per kg, obtained by apheresis from her haplo-identical mother, were infused. Engraftment was enhanced with GCSF from day 6 until neutrophils were up to 1 × 10 9 /L. Engraftment occurred on day 18 (neutrophils40.5 × 10 9 /L). Chimerism evaluation on day 30 was full donor type. Bone marrow evaluation at day 30 showed a normal cellularity with no blast excess.
At day 22, she developed a grade 3 BK virus hemorrhagic cystitis, requiring repeated clot removal procedures. This painful act was managed with premixed 50% NO and O 2 (MEOPA) daily administration. The prescription was initially not limited but given as requested by the patient, with a median time of exposure of 4 h, and a maximum of 8 h a day. From day 48, we limited the daily prescription to a maximum of 1 h in total per day. By day 48, a progressive and profound decrease of white blood cell count below 0.5 × 10 9 /L was observed ( Figure 2 ). Daily platelet and weekly red cell transfusions were required, due to hemorrhagic cystitis. The reticulocyte count was lower than 10 × 10 9 /L, suggesting a central mechanism. The patient did not develop fever, rash, neurologic symptoms or any sign of graft versus host disease. Hematologic toxicity from other drugs used at the time (imipenem and voriconazole) was excluded, and no improvement was observed after stopping mycophenolate mofetil on day 49. Blood tests did not show any sign of hemolysis. RNA viral detection in the blood was negative for CMV, HHV6, parvovirus B19, EBV and adenovirus.
A bone marrow analysis performed on day 55 revealed a normal cellularity with no excess of blasts, excluding a disease relapse. The erythroid lineage was abnormal, showing hyperplasia and megaloblastosis. The granulocytic compartment was characterized by a relative excess of myelocytes and promyelocytes without maturation blockade. Blood tests showed a moderate deficiency of vitamin B12 (142 pg/mL, normal range: 180-820 pg/mL), and the patient did receive a systemic treatment with folate. The homocystein level was not measured. Bone marrow revealed megaloblastic anemia, which cannot be explained by a moderate Cobalamine is used as a co-enzyme of methionine synthetase (MS). MS transforms 5-methyl-tetrahydrofolate into THF. THF is then used for the synthesis of purine and pyrimidine nitrogenous bases of DNA. NO inactivates vitamin B12, by oxidation of its cobalt core. DHF = dihydrofolate; dTDP = desoxythymidine diphosphate; dTMP = desoxythymidine monophosphate; dTTP = desoxythymidine triphosphate; dUMP = deoxyuridine monophosphate; MS = Methionine synthetase; THF = tetrahydrofolate.
vitamin B12 deficiency. As the presentation contrasted with the relatively modest degree of cobalamine deficiency, we suspected it could represent an adverse effect of NO. MEOPA administration was then stopped at day 54 and IV vitamin B12 supplement was started. As shown on Figure 2 , 3 days after NO was stopped, the reticulocyte and neutrophil counts increased and reached 430 × 10 9 /L and 1 × 10 9 /L on day 59, respectively. Bone marrow control, performed 3 weeks later, did not show any sign of megaloblastosis. The quick hematologic improvement after stopping NO gas exposure argued for its causality.
Hematopoietic adverse effects of NO were first described in 1956 by Lassen et al., 6 who reported 13 cases of tetanus patients, treated with prolonged exposure to NO and who developed megaloblastic anemia within a week. Since then, other authors reported NO impact on bone marrow after anesthestic procedures. 3, 7 The delay of hematologic recovery observed in this case is compatible with the physiopathology of NO toxicity on cobalamine. NO inactivates vitamin B12 by oxidation of its cobalt core. This oxidation is irreversible, and the delay observed in several studies for methionin synthetase activity to recover is about 3-4 days. 8 The current case confirms the important deleterious effect of NO on haematopoiesis. A dose-dependent effect is described when NO is used for 46 h, but has also been observed after short-term repeated exposures. 7 In fact, as we reduced the maximal duration of NO to o 1 h per day after day +48, we observed a rapid normalization of the leukocyte count and improvement of the anemia. This complication is not so frequent when using NO for patients with normal haematopoiesis. Actually, Lauvin et al. 9 reported a French monocentric experience of repeated analgesic use of MEOPA for 420 min each time, in five patients, with no case of hematologic impairment. In a standard anesthesia use (9-h administration), Waldman et al. 10 did not find any significant decrease in reticulocytes, platelets or leukocytes count in exposed patients compared with nonexposed patients. From this current case, we can hypothesize that patients who received a recent SCT or who are treated for a hematologic disease, may have an increased susceptibility to NO medullar toxicity. In order to avoid this toxicity, Amos et al.
11
reported a protective effect of systemic acid folinic substitution, used to reduce hematological deleterious effects in 11 patients subjected to a 24-h long anesthetic administration of NO. This strategy may be extended to other NO-exposed patients.
In conclusion, this case highlights an infrequent and probably underestimated cause of post-transplant reversible bone marrow failure, due to the inhibiting action of NO on cobalamine metabolism. Pain control may justify NO administration, but this treatment needs to be limited in duration, associated with systemic vitamin B12 prophylaxis, and closely monitored, especially in this high-risk population.
CONSENT
A written informed consent (copy available on demand) was obtained from the patient for publication of this case report. MEOPA was given from day +22 to day +47 after transplant with no limitation; then the exposure was limited to 1-h time daily from day +48 until day +54, when it was completely stopped. We observed a quick elevation of both WBC and reticulocyte count after the exposure to NO was stopped.
